Astrocytic Tumor

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ALK
ALK Fusion
ARAF
ARAF Mutation
BRAF
BRAF Fusion
BRAF Mutation
BRAF V600A
BRAF V600D
BRAF V600E
BRAF V600G
BRAF V600K
BRAF V600M
BRAF V600R
CRKL
CRKL Mutation
FGFR1
FGFR1 Mutation
FGFR2
FGFR2 Mutation

FGFR3
FGFR3 Mutation
H3F3A
H3F3A Codon 34 Missense
H3F3A Codon 35 Missense
H3F3A K27M
H3F3A K28M
HRAS
HRAS Mutation
IDH1

IDH1 Mutation
IDH2
IDH2 Mutation
KRAS
KRAS Mutation
MAP2K1
MAP2K1 Mutation
MAP2K2
MAP2K2 Mutation
MAP2K4

MAP2K4 Loss
MAP2K4 Mutation
MAP3K1
MAP3K1 Loss
MAP3K1 Mutation
MAPK1
MAPK1 Mutation
MYB
MYB Mutation
MYBL1

MYBL1 Mutation
NF1
NF1 Loss
NF1 Mutation
NF2
NF2 Loss
NF2 Mutation
NRAS
NRAS Mutation
NTRK1

NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion
PTPN1
PTPN1 Mutation
RAF1
RAF1 Mutation
ROS1

ROS1 Fusion
SOS1
SOS1 Mutation
SRC
SRC Mutation

Overview

NCI Definition: A glial tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and glioblastoma. [1]

Astrocytic tumors most frequently harbor alterations in TP53, CDKN2A, PTEN, EGFR, and CDKN2B [2].

Most Commonly Altered Genes in Astrocytic Tumor

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, CDKN2A Loss, and CDKN2B Loss are the most common alterations in astrocytic tumor [2].

Top Alterations in Astrocytic Tumor

Clinical Trials

View Clinical Trials for Astrocytic Tumor

There is 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are completed or closed. Of the trial that contains astrocytic tumor as an inclusion criterion, 1 is phase 1/phase 2 (1 open).

ARAF, BRAF, and CRKL are the most frequent gene inclusion criteria for astrocytic tumor clinical trials [3].

Trials Investigating Astrocytic Tumor by Gene and Recruiting Status

Mirdametinib is the most common intervention in astrocytic tumor clinical trials.

Drugs Being Investigated in Astrocytic Tumor Trials by Recruiting Status

Significant Genes in Astrocytic Tumor

ARAF +

ARAF is altered in 1.13% of astrocytic tumor patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF +

BRAF is altered in 7.58% of astrocytic tumor patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL +

CRKL is altered in 0.59% of astrocytic tumor patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 +

FGFR1 is altered in 3.82% of astrocytic tumor patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 1.42% of astrocytic tumor patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 +

FGFR3 is altered in 3.28% of astrocytic tumor patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS +

HRAS is altered in 0.64% of astrocytic tumor patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS +

KRAS is altered in 1.76% of astrocytic tumor patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 +

MAP2K1 is altered in 0.9% of astrocytic tumor patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 +

MAP2K2 is altered in 0.99% of astrocytic tumor patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 +

MAP2K4 is altered in 0.82% of astrocytic tumor patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 +

MAP3K1 is altered in 2.65% of astrocytic tumor patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 +

MAPK1 is altered in 0.55% of astrocytic tumor patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYB +

MYB is altered in 0.53% of astrocytic tumor patients [2].

MYB is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MYB status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 +

MYBL1 is altered in 1.22% of astrocytic tumor patients [2].

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 +

NF1 is altered in 16.97% of astrocytic tumor patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF2 +

NF2 is altered in 1.3% of astrocytic tumor patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is altered in 0.79% of astrocytic tumor patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTPN1 +

PTPN1 is altered in 0.62% of astrocytic tumor patients [2].

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 +

RAF1 is altered in 1.09% of astrocytic tumor patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SOS1 +

SOS1 is altered in 2.64% of astrocytic tumor patients [2].

SOS1 is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC +

SRC is altered in 0.76% of astrocytic tumor patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

Astroglioma, Astrocytic Neoplasm

Parent(s)

Glioma

Children

Low Grade Astrocytic Tumor, Gliofibroma, High Grade Astrocytic Tumor, and Astrocytoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Astrocytic Tumor

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Astrocytic Tumor

Disease Details

References

About

Molecular Medicine

Content Types